TYK Medicines, Inc (HKG:2410)

Market Cap	9.94B
Revenue (ttm)	113.87K
Net Income (ttm)	-411.79M
Shares Out	370.84M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,697,500
Average Volume	2,850,200
Open	30.45
Previous Close	30.45
Day's Range	26.00 - 30.45
52-Week Range	12.86 - 56.55
Beta	n/a
RSI	42.50
Earnings Date	May 30, 2025

About TYK Medicines

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-depe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 153
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2410

Financial Performance

Financial numbers in CNY